Dyadic International Inc. Common Stock (DYAI)

About DYAI

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sect…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

5

Website

dyadic.com/

Fundamentals

1-day range

$0.6$0.65

Market cap

$37.17M

P/E (trailing)

—

P/E (forward)

-1.92

EPS (trailing)

$-0.23

Dividend yield

—

Beta

0.96

Avg. volume

222.0K

Forecasts

2 analyst ratings

Dyadic International Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• DYAI

  Dyadic International Inc. Common Stock

  $0.6207

  ▼ 3.02%
  Market cap $37.17MP/E —
  $0.6197$1.6
• ELUT

  Elutia Inc. Class A Common Stock

  $0.885

  ▲ 0.57%
  Market cap $38.95MP/E 0.75
  $0.5$2.4
• ALGS

  Aligos Therapeutics Inc. Common Stock

  $6.93

  ▼ 1.98%
  Market cap $34.10MP/E —
  $3.98$13.69
• TVGN

  Tevogen Inc. Common Stock

  $6.89

  ▲ 2.07%
  Market cap $41.58MP/E —
  $3.64$49.5
• ESLA

  Estrella Immunopharma Inc. Common Stock

  $0.705

  ▼ 2.10%
  Market cap $32.10MP/E —
  $0.6781$3.15
• MGX

  Metagenomi Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $46.68MP/E —
• EXOZ

  eXoZymes Inc. Common Stock

  $7.17

  ▼ 0.10%
  Market cap $47.57MP/E —
  $4.35$18.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor
  Benzinga · 8/13/2026
• Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate
  Benzinga · 8/12/2026
• Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins
  Benzinga · 8/4/2026

• Francisco Trust under agreement dated February 28, 1996 · July 24, 2026 · Sale

  2.6K @ $1.21
• Francisco Trust under agreement dated February 28, 1996 · July 23, 2026 · Sale

  54.8K @ $1.3
• Francisco Trust under agreement dated February 28, 1996 · July 22, 2026 · Sale

  38.0K @ $1.33

Institutional Ownership

March 31, 2026

Total shares held

5.07M

Total value held

$4.15M

Institutional holders

34